REMoDL-B clinical trial: results presented at ASH 2015

Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical trial, a Phase III study for untreated diffuse large B-cell lymphoma patients. The aims of this study were to compare R-CHOP plus bortezomib to R-CHOP alone, as front-line therapy. The trial also aimed to develop a gene expression profiling test to determine the genetic sub-type (ABC or GCB), and if the different sub-types would have an increased benefit from the addition of bortezomib therapy.